ReviewFrontiers in immunology2022
Revealing Clonal Responses of Tumor-Reactive T-Cells Through T Cell Receptor Repertoire Analysis.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- A Tumor-Boundary Niche Enriched for PD-1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatiotemporal CD8Cancer science · 2026Review
- Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer.Cancers · 2026Article
- An integrated machine learning and mendelian randomization approach identifies SERPING1 as a prognostic biomarker associated with CD8 + T-cell infiltration in DLBCL.Discover oncology · 2026Article
- Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor.International journal of biological sciences · 2026Article
- Reframing the paradigm: stereotactic body radiation therapy as an engineer of the tumor immune microenvironment.Frontiers in immunology · 2026Review
- Discovery and validation of proliferative exhausted T cells as a favorable prognostic biomarker in esophageal squamous cell carcinoma.Scientific reports · 2025Article
- Granulocyte colony-stimulating factor induced T-cell hyporesponsiveness via modulation of CD177Clinical and translational medicine · 2025Article
- Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosis.Cancer immunology, immunotherapy : CII · 2025Article
- Radical hemithorax radiotherapy induces an increase in circulating PD-1Frontiers in immunology · 2025Article
- Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.Cancer immunology research · 2024Article
- Unlocking the potential of T-cell metabolism reprogramming: Advancing single-cell approaches for precision immunotherapy in tumour immunity.Clinical and translational medicine · 2024Review
- Characterization of the T-cell receptor repertoire associated with lymph node metastasis in colorectal cancer.Frontiers in oncology · 2024Article
- TIGIT, a novel immune checkpoint therapy for melanoma.Cell death & disease · 2023Review
- TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.Cell reports methods · 2023Article
- Immune repertoire profiling for disease pathobiology.Pathology international · 2023Review
- Association of genes in hereditary metabolic diseases with diagnosis, prognosis, and treatment outcomes in gastric cancer.Frontiers in immunology · 2023Article
- T-cell repertoire diversity: friend or foe for protective antitumor response?Journal of experimental & clinical cancer research : CR · 2022Review
- TCR repertoire and transcriptional signatures of circulating tumour-associated T cells facilitate effective non-invasive cancer detection.Clinical and translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.